Rotaqor

Atorvastatin

Method of action: Hypocholesterolemic, Inhibiting Hmg-Coa Reductase, Lipid Modifying Agents, Lipid-Lowering

Treatment option: Hyperlipidemia, Hypercholesterolemia, Prevention Of Cardiovascular Disease, Familial Hypercholesterolemia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rotaqor

What is Rotaqor?

Rotaqor is a pharmacological treatment belonging to the class of medications known as statins, or HMG-CoA reductase inhibitors. It is primarily utilized in the management of lipid disorders, specifically targeting the regulation of cholesterol levels within the bloodstream.

Mechanism of Action

The active component in Rotaqor works by inhibiting a specific enzyme in the liver responsible for the production of cholesterol. By reducing the endogenous synthesis of cholesterol, the medication helps to lower the levels of low-density lipoprotein (LDL), often referred to as "bad" cholesterol, and triglycerides. Simultaneously, it may contribute to a modest increase in high-density lipoprotein (HDL), or "good" cholesterol.

Therapeutic Purpose

Rotaqor is indicated for individuals diagnosed with hyperlipidemia or mixed dyslipidemia when dietary changes and lifestyle modifications alone are insufficient to reach target lipid levels. The primary goals of treatment include:

Reduction of LDL Cholesterol: Lowering high levels of LDL to decrease the accumulation of fatty deposits in the arterial walls.
Management of Triglycerides: Addressing elevated fats in the blood that contribute to cardiovascular risk.
Total Cholesterol Regulation: Improving the overall lipid profile to support long-term cardiovascular health.

Role in Long-term Management

As a chronic treatment, Rotaqor is intended to be used as a complement to a heart-healthy diet and regular physical activity. It serves as a foundational therapy for patients at risk of atherosclerotic cardiovascular disease, aiming to stabilize existing plaques and prevent the progression of arterial narrowing.

Regulatory References

What side effects are possible with Rotaqor?

Adverse Reaction Scope

Rotaqor (Atorvastatin) is associated with adverse reactions that are classified by regulatory authorities according to frequency, using categories such as Common, Uncommon, Rare, Very Rare, and Not Known. These effects involve multiple System-Organ Classes (SOCs), including Musculoskeletal, Nervous System, Gastrointestinal, and Hepatobiliary disorders.

Classification	Examples of Officially Listed Effects
Common	Nasopharyngitis, Hyperglycaemia, Headache, Diarrhoea, Myalgia, Arthralgia.
Rare/Very Rare	Thrombocytopenia, Peripheral neuropathy, Hepatic failure, Rhabdomyolysis.

Serious Adverse Reactions and Constraints

The label documents specific serious adverse reactions, most notably Rhabdomyolysis, a severe muscle condition that can potentially lead to acute kidney injury, and Hepatic Failure (fatal and non-fatal cases). Immune-mediated necrotizing myopathy (IMNM) is also listed with a Not Known frequency.

Safety-related constraints defined in regulatory documents include contraindications for patients with Active Liver Disease and those with unexplained persistent elevations of serum transaminases (liver enzymes) exceeding three times the upper limit of normal. Furthermore, use is generally not recommended during Pregnancy or Lactation due to the potential for fetal harm. Older Adults (age 65 years) are noted in labeling as having an increased risk for myopathy and rhabdomyolysis.

Regulatory Safety Summary

The majority of listed adverse effects are Common and affect several organ systems.
The safety profile highlights the rare but critical risk of severe muscle damage and liver failure, which are formally documented.
The use of the medication is formally restricted for individuals with active liver impairment and is contraindicated with specific hepatitis C antiviral agents (glecaprevir/pibrentasvir).

The official safety information formally structures the risk profile by categorizing all documented effects by frequency and system involvement, providing a factual basis for understanding the medicine's constraints. It explicitly defines rare, serious adverse events and identifies specific patient populations or drug combinations where use is officially contraindicated.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory guidance for Rotaqor (Atorvastatin) overdose emphasizes immediate action and comprehensive supportive clinical management. A distinct set of acute clinical symptoms specific to an Atorvastatin overdose is generally not defined in regulatory prescribing information, directing focus toward procedural response.

Officially Documented Overdose Profile

Aspect	Regulatory Guidance
Specific Symptoms	No specific acute symptom profile is consistently described. Overdose carries the theoretical potential for exacerbation of known dose-related adverse reactions, such as severe myopathy or rhabdomyolysis.
Antidote Availability	No specific antidote is known to exist for Atorvastatin overdose according to regulatory labeling.
Management Focus	Treatment must be symptomatic and supportive. Procedures like gastric lavage or the administration of activated charcoal may be considered to reduce gastrointestinal absorption.
Clearance Constraint	Hemodialysis is not expected to be an effective method for significantly enhancing the clearance of Atorvastatin due to the drug’s extensive plasma protein binding.

Required Emergency Action

Immediate medical attention must be sought for any suspected overdose of Rotaqor. This action is mandated due to the lack of a known antidote and the crucial need for prompt clinical assessment and supportive care to manage potential complications. Individuals must contact emergency services immediately if they observe severe signs such as collapse, difficulty breathing, or seizures. The patient may require hospital observation and continuous clinical monitoring.

Therapeutic Uses of Rotaqor

What Rotaqor Treats: Main Uses and Benefits

Rotaqor (Atorvastatin) is generally used for managing symptoms related to systemic imbalance, primarily for primary and mixed dyslipidemia, which are conditions involving elevated levels of harmful lipids. The key therapeutic advantage is that this management supports general well-being during symptomatic phases associated with metabolic conditions.

The medication is considered relevant for addressing silent atherosclerotic disease progression, a clinical condition involving plaque buildup in the arteries. The treatment is applied in addressing the progression of plaque and may assist with mitigating the advancement of the condition. This intervention offers a therapeutic advantage by helping to reduce the probability of future life-threatening incidents, including Heart Attack and Stroke. The treatment provides support that helps ease the overall burden of risk.

It is commonly used for both primary and secondary prevention in high-risk groups, including patients with established Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Heart Disease (CHD), or Type 2 Diabetes Mellitus with risk factors, as well as specific cases of Familial Hypercholesterolemia.

Quick Fact: Risk Mitigation Focus
Relief for: Systemic Imbalance
Commonly Applied in: Scenarios requiring long-term support that is relevant for easing the risk of major cardiovascular events.

Regulatory References

Atorvastatin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Rotaqor

The eligibility profile for Rotaqor (Atorvastatin) is strictly defined by regulatory authorities and centers on age, reproductive status, and liver function.

Eligibility scope	Official Regulatory Finding
Populations for whom use is allowed	Adult patients are eligible for all labeled indications. Pediatric patients aged 10 years and older are eligible for specific Familial Hypercholesterolemia (HeFH/HoFH) indications.
Populations for whom use is contraindicated	Patients with Active Liver Disease or unexplained persistent elevations of serum transaminases (3x ULN). Patients with known Hypersensitivity to the active substance or excipients.
Pregnancy and lactation eligibility	Pregnancy is an absolute contraindication. Lactation (Breastfeeding) is an absolute contraindication. Females of reproductive potential must use effective contraception during treatment.
Age-related eligibility rules	Use is not established for children younger than 10 years of age for any indication. Older adults (age 65+) are eligible, but advanced age is noted as a predisposing risk factor for myopathy.
Condition-specific eligibility rules	Use requires caution in patients with a history of Hepatic Impairment or substantial alcohol consumption. Renal Impairment and Uncontrolled Hypothyroidism are listed as predisposing factors for myopathy, affecting the eligibility decision prior to initiation.

Regulatory documents define eligibility through a framework of absolute prohibitions (contraindications for liver disease, pregnancy, and hypersensitivity) and conditional use rules that specify the approved minimum age (10 years) and mandate caution for groups with predisposing risk factors, strictly delimiting the population authorized to use the medicine.

What should I know about interactions with other medicines?

The use of Rotaqor (rosuvastatin) can be affected by other medicines and products due to effects on drug absorption, systemic exposure, or additive pharmacodynamic effects. The official interaction profile primarily involves transporter-mediated interactions and agents that increase the risk of muscle-related side effects.

Exposure-Modifying Interactions

Rosuvastatin is a substrate for certain drug transporters, including OATP1B1 and BCRP. Co-administration with inhibitors of these transporters, such as the immunosuppressant Cyclosporine or specific Anti-HIV/HCV agents (e.g., Lopinavir/Ritonavir, Sofosbuvir/Velpatasvir/Voxilaprevir), can substantially increase rosuvastatin plasma concentrations. This may require dosage modification or, in some cases, renders the combination not recommended.

Pharmacodynamic Risk

Combining Rotaqor with other lipid-modifying agents, such as fibrates (e.g., Gemfibrozil) or high-dose Niacin (ge 1 g/day), carries a documented additive risk of muscle-related adverse events. Additionally, co-administration with Colchicine may also increase this risk.

Timing and Monitoring

Antacids containing aluminum and magnesium hydroxide interfere with rosuvastatin absorption and should be taken at least two hours after a Rotaqor dose to mitigate a decrease in effectiveness. For patients taking Warfarin, the International Normalized Ratio (INR) requires frequent monitoring upon initiating or changing the Rotaqor dosage.

Mechanism of Action

How Rotaqor Works: The Mechanism of Action

Rotaqor acts by directly engaging and inhibiting the enzyme HMG-CoA reductase in the liver, which is the key component in the body's internal cholesterol production pathway. This competitive inhibition immediately restricts the supply of newly synthesized cholesterol, initiating a subsequent homeostatic change within liver cells.

The resulting drop in intracellular cholesterol triggers an immediate feedback mechanism, leading to a net upregulation of Low-Density Lipoprotein (LDL) receptors on the liver cell surfaces. This enhanced receptor expression accelerates the LDL clearance pathway, promoting the removal of LDL-C from the systemic circulation and resulting in a decrease in circulating LDL-C levels.

Beyond lipid regulation, Rotaqor influences the vascular environment through a mechanism known as pleiotropy. By reducing critical downstream intermediates of the mevalonate pathway (isoprenoids), the drug modulates signaling proteins in blood vessel walls. This effect contributes to the modulation of endothelial cell stability and alters the pathways that govern systemic vascular inflammatory response, which establishes the full scope of the mechanism’s action on the body.

Dosage and Administration Information

How to use Rotaqor: Administration Guidelines

Rotaqor (Atorvastatin) is administered via the oral route as film-coated tablets. The usage protocol is standardized for administration across clinical practice.

Administration Scope

The medicine is taken once daily as a single dose. The tablet may be taken with or without food and at any time of the day to simplify patient adherence. The dose typically starts at 10 mg or 20 mg once daily and may be titrated up to a maximum recommended dose of 80 mg daily. Rotaqor is supplied in strengths of 10 mg, 20 mg, 40 mg, and 80 mg.

Population-Specific and Titration Rules

The instructions outline specific use criteria for certain populations. For patients with renal impairment, no dosage adjustment is required. In pediatric patients (10–17 years) receiving treatment for Heterozygous Familial Hypercholesterolemia, the dose is limited to a maximum of 20 mg daily. The dose is subject to adjustment at intervals of four weeks or more following initiation, based on assessment of the ongoing therapeutic response.

Procedural Requirements

If a scheduled dose is missed, it must be skipped if more than 12 hours have elapsed since the required time, and the patient must then resume the regular dosing schedule. Additionally, specific dosage limits must be observed when Rotaqor is co-administered with certain other medications, such as reducing the maximum daily dose to 20 mg when taken alongside certain macrolide antibiotics or antivirals.

Connection to the Overall Use Protocol

This structured administration protocol establishes Rotaqor as a chronic therapy taken daily by mouth. The flexibility concerning food intake and time of day facilitates consistent long-term use. The mandatory four-week minimum interval for dose adjustment defines the standardized procedural step for managing the long-term treatment plan.

Recent Clinical Evidence

Research evidence / Overview of studies for Rotaqor

Rotaqor (Atorvastatin) was studied for its use in managing high blood lipids, and research explored its use in populations with risks associated with cardiovascular disease. The evidence for this medication was observed in large-scale Randomized Controlled Trials (RCTs), where people are randomly assigned to receive either the medicine or a placebo, and from subsequent long-term follow-up research.

Evidence for use in Managing Elevated Blood Lipids (Dyslipidemia)

Research primarily involved short-term RCTs that monitored the change in specific biomarkers, including the so-called "bad cholesterol" (LDL-C) and triglycerides. The data show patterns related to the measured change in these lipid markers in various adult populations with hyperlipidemia. These initial trials were not designed to assess long-term major cardiovascular event outcomes. Furthermore, evidence is limited for certain rare genetic subtypes of high cholesterol, such as Homozygous Familial Hypercholesterolemia (HoFH).

Evidence for Primary Prevention of Cardiovascular Events

Primary prevention research was evaluated in adults who had risk factors like high blood pressure or type 2 diabetes. These large-scale, long-term RCTs research examined a composite of major events, including non-fatal heart attack, fatal and non-fatal stroke, and the need for revascularization procedures. These studies described patterns of lower incidence of the combined major event endpoint in the group receiving the medicine compared to the placebo group.

Evidence for Secondary Prevention in Patients with Established Disease

Secondary prevention research was studied for patients with established Atherosclerotic Cardiovascular Disease (ASCVD), such as those who have previously experienced a heart attack or stroke. The trials describe patterns related to event rates for the composite endpoint between the groups observed in the trials. An association was observed in some studies regarding the highest dose and the occurrence of hemorrhagic stroke.

Long-term Follow-up and Durability of Response

The longest duration of follow-up for participants in key outcome trials has been monitored for up to 20 years in some observational settings. These follow-up studies contribute to the broader evidence landscape, although controlled comparative evidence is lacking for very long durations due to patient crossover to active treatment.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Rotaqor (FAQ)

Q: What is Rotaqor used for?

According to official product information, Rotaqor is prescribed to help manage high levels of cholesterol and certain fats, known as triglycerides, in the blood. It is also used to help reduce the overall risk of serious heart and circulation problems in specific adult patients. This medication is part of a broader treatment plan that typically includes diet and exercise modifications.

Q: Can I stop taking Rotaqor once my cholesterol is at target?

Regulatory documents state that treatment with Rotaqor is typically a long-term commitment. Stopping the medication without consulting a healthcare professional may result in cholesterol levels potentially increasing again. The effectiveness of the drug, as generally described in the label, depends on continuous use as directed.

Q: Does Rotaqor interact with grapefruit juice?

Studies and official information indicate that there is no known interaction between Rotaqor and grapefruit juice, so consumption is generally considered acceptable. However, this medicine can interact with several other prescription and non-prescription products. Patients are generally advised to consult the official documentation for complete interaction information.

Q: How long does it take for Rotaqor to start working?

Official product information indicates that the medication begins to act relatively quickly. A significant reduction in cholesterol levels is often observed within one week of starting treatment. The maximum intended cholesterol-lowering effect is generally reached after approximately two to four weeks of continuous daily use.

Q: Is Rotaqor suitable for pregnant women?

Rotaqor is contraindicated, meaning it must not be used, during pregnancy or while breastfeeding. Furthermore, official product information indicates that women of childbearing potential should use reliable and effective contraception throughout the entire course of treatment.

Q: Can I drink alcohol while on Rotaqor?

According to the Patient Information Leaflet, excessive alcohol consumption is generally advised against while taking this medicine. High alcohol intake may increase the risk of certain side effects, specifically those affecting the liver. The patient information leaflet suggests discussing your habits with a healthcare provider to understand suitable consumption limits.

Q: What happens if I miss a dose of Rotaqor?

If a dose is forgotten, the official patient information advises taking it as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should generally be skipped. The regulatory information cautions against taking a double dose to compensate for a forgotten one.

How should Rotaqor be stored and disposed of?

How to Store and Dispose of Rotaqor?

The storage and disposal of Rotaqor (Atorvastatin Calcium) must follow strict regulatory guidelines to maintain product quality and ensure safety.

Official Storage Conditions

Rotaqor tablets must be stored at Controlled Room Temperature (CRT), which is defined as 20 C to 25 C ( 68 F to 77 F). The product requires protection from moisture and must be kept in its original container.

All medicines must be stored out of the sight and reach of children.

Disposal Procedures

Disposal of unused or expired Rotaqor should be carried out according to local requirements. The preferred method is using a drug take-back program. Medicines should not be disposed of via wastewater or household waste unless specifically advised by regulatory documents.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Malaysia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z